Salute e Benessere

Novo Nordisk A/S - share repurchase programme

Bagsværd, Denmark, 08 January 2024– On 6 November 2023, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the "Safe Harbour Rules"). This programme is part of the overall share repurchase programme of up to DKK 30 billion to be executed during a 12-month period beginning 1 February 2023. Under…
Nasdaq GlobeNewswire
08/01/2024

Nutraceutical Excipients Market worth $6.1 billion by 2028 - Exclusive Report by…

Browse in-depth TOC on "Nutraceutical Excipients Market" Browse in-depth TOC on "Nutraceutical Excipients Market" 298 – Tables 66 – Figures 391 – Pages The organic chemicals product source of the nutraceutical excipients segment is driving the market due to consumer preference for natural products, reduced allergenic potential, and clean label trend. The burgeoning nutraceutical excipients market is fueled by the escalating consumer demand for natural and organic…
PR Newswire
08/01/2024

Virbac : Declaration of the number of shares and voting rights 12/2023

DECLARATION OF THE NUMBER OF SHARES AND VOTING RIGHTS Information on the total number of voting rights and of shares representing the share capital (Article 223-16 of the General regulations of the French Financial Market Authority – Autorité des Marchés Financiers)Quotation place: Euronext Paris Compartiment A ISIN code: FR0000031577DateTotal number of shares representing the share capitalTotal number of voting rightsDecember, 31 20238 458 000Gross total of voting...
Nasdaq GlobeNewswire
08/01/2024

WuXi Biologics to Increase Manufacturing Capacity in Massachusetts

WuXi Biologics currently employs over 400 people in the U.S., and the Worcester facility will create an additional 200 new jobs when fully operational. WuXi Biologics currently employs over 400 people in the U.S., and theWorcesterfacility will create an additional 200 new jobs when fully operational. Dr.Chris Chen, CEO of WuXi Biologics, noted, "The new commercial capacity inWorcester, Massachusettsrepresents a key part of our global biomanufacturing network, reflecting...
PR Newswire
08/01/2024

Orion Corporation: Managers' transactions – Ari Lehtoranta

ORION CORPORATIONMANAGERS' TRANSACTIONS08 JANUARY 2024 at 11.00 EET Orion Corporation: Managers' transactions – Ari Lehtoranta Orion Corporation has received the following disclosure under Market Abuse Regulation (EU) No 596/2014, regarding transactions with shares and linked securities in Orion Corporation made by managers and their closely associated persons.Orion Oyj - Managers' Transactions ____________________________________________ Person subject to the notification...
Nasdaq GlobeNewswire
08/01/2024

EUROPEAN LIFE SCIENCES INVESTORS UPBEAT ABOUT 2024 OUTLOOK

While investors remain discerning, plenty of 'dry powder' is available for the right investment While investors remain discerning, plenty of 'dry powder' is available for the right investment Against this backdrop, clear communication has never been more important LONDON,Jan. 8, 2024/PRNewswire/ -- Optimum Strategic Communications ('Optimum'), the international strategic healthcare communications firm, today announces the results of its 2024 survey of European life sciences...
PR Newswire
08/01/2024

Diamyd Medical gains market research findings to guide U.S. commercial strategy

Pricing Insights: The research, undertaken by the US-based consultancy, Kondrad Consulting Group1, involved detailed interviews with both national and regional payers, collectively responsible for healthcare coverage of approximately 77 million commercial lives in the United States. These interviews suggest a potential price range of USD 194,000 - 240,000 for Diamyd®, based on effective delivery of its unique product profile targeted at a specific genetic subgroup of type 1 diabetes patients…
PR Newswire
08/01/2024

Clarivate Identifies Thirteen Potential Blockbuster Drugs and Gamechangers in…

This year, analysts identified 13 new-to-market therapeutics and drugs poised to launch in 2024 which Clarivate predictive analytics project will achieve blockbuster status by 2029 or deliver game-changing benefits to patients. These promising advancements include a broad spectrum of therapeutic innovation for conditions including breast cancer, hemophilia A, sickle cell disease, Crohn's disease, ulcerative colitis, respiratory syncytial virus (RSV) and multiple myeloma, among others. This...
PR Newswire
08/01/2024

Alimentiv Announces Pierre Gaudreault as New Chief Executive Officer

"We are thrilled to welcome Pierre as our new CEO. His extensive experience, strategic vision, and commitment to relationships, diversity, and inclusion align seamlessly with Alimentiv's values. Pierre's wealth of experience will be invaluable to the organization's strategic vision and continued growth. "We are thrilled to welcome Pierre as our new CEO. His extensive experience, strategic vision, and commitment to relationships, diversity, and inclusion align seamlessly with…
PR Newswire
08/01/2024

Calliditas Therapeutics provides business update ahead of JP Morgan conference

"We are very pleased with the preliminary outcome of the 2023 fiscal year, generating product sales in excess of $100 million in our second year of commercialisation. This is a very strong result and we are very excited about 2024 based on the recent full approval of TARPEYO in the US, strengthened product protection and the record growth seen in enrollments in Q4. This result, in combination with our successful debt refinancing and strengthening our US leadership team, puts us in an…
PR Newswire
08/01/2024

Guardant Health and Hikma Partner to Offer Cancer Screening and Comprehensive…

Guardant Health serves more than 60 countries globally with its tests, and this partnership with Hikma will improve access to Guardant's next-generation sequencing (NGS) tests in the Middle East and North Africa, where cancer cases are estimated to double by the year 2040.[1] Guardant Health serves more than 60 countries globally with its tests, and this partnership with Hikma will improve access to Guardant's next-generation sequencing (NGS) tests in theMiddle EastandNorth Africa, where...
PR Newswire
08/01/2024

Disclosure notification from AOC Pharma S.à r.l. – passing 10% threshold

Regulated information Nazareth (Belgium)/Rotterdam (The Netherlands), 8 January 2024 – 8AM CET Disclosure notification from AOC Pharma S.à r.l. – passing 10% threshold On 27 December 2023, Fagron received a notification pursuant to the Belgian law of 2 May 2007 regarding the disclosure of major shareholdings in listed companies from AOC Pharma S.à r.l., an entity controlled by the value investor Active Ownership, that its shareholding crossed the 10% disclosure threshold as the result of...
Nasdaq GlobeNewswire
08/01/2024

Cumulus Oncology raises £9m in seed financing

Cumulus Oncology raises £9m in seed financingEos Advisory-led round includes new corporate investor the Scottish National Investment Bank Proceeds from the financing will be used to support Cumulus Oncology's future growth plans, expand its portfolio and accelerate the development of new cancer treatments from discovery towards clinical Proof of Concept Edinburgh, Scotland, 08 January 2024– Cumulus Oncology (“Cumulus” or “the Company”), which operates Europe's first oncology...
Nasdaq GlobeNewswire
08/01/2024

Mendus to participate in several investor and industry conferences in January

Press release Stockholm, Sweden, January 8, 2024Mendus AB ("Mendus" publ; IMMU. ST), a biopharmaceutical company focused on immunotherapies targeting tumor recurrence, today announced that it will participate in the following upcoming investor and industry conferences:42 ndAnnual J.P. Morgan Healthcare ConferenceSan Francisco, USA, January 8-11, 2024Mendus management team will be in San Francisco for business and investor meetings during the J.P, Morgan conference ...
Nasdaq GlobeNewswire
08/01/2024

Orion and Glykos announce research collaboration and licensing agreement to…

ORION CORPORATIONPRESS RELEASE8 JANUARY 2024 at 09.00 EET Orion and Glykos announce research collaboration and licensing agreement to develop next-generation ADCs Orion Corporation and Glykos Finland Oy announced today that they have entered into a research collaboration and licensing agreement to develop next-generation antibody-drug conjugates (ADCs).Under the agreement, Orion gains access to Glykos' proprietary ADC technologies, initiating an ADC program with the...
Nasdaq GlobeNewswire
08/01/2024

Essential Pharma acquires European rights to Colobreathe®(colistimethate sodium)…

Essential Pharma acquires European rights to Colobreathe®(colistimethate sodium) from Teva Colobreathe® is an inhaled antibiotic for the management of chronic Pseudomonas aeruginosainfections in cystic fibrosis patientsThe acquisition will help ensure continued access to an important medicine for this vulnerable patient populationFirst rare disease medicine to be added to the Essential Pharma product portfolioZug, Switzerland and Egham, UK – 8 January 2024– Essential...
Nasdaq GlobeNewswire
08/01/2024

Groupe Casino: Update on financial restructuring conditions precedent; European…

Update on financial restructuring conditions precedentEuropean Commission merger control clearance Paris, 8 January 2024Casino announces that on 5 January 2024, the European Commission issued a decision authorizing, under merger control, the consortium (composed of EP Equity Investment IIIs.à.r.l., Fimalac and Attestor) to take control of the Group as part of the financial restructuring, it being specified that the consortium's acquisition vehicle will be controlled by EP Equity...
Nasdaq GlobeNewswire
08/01/2024

Nicox : Half-year liquidity contract statement with Kepler Cheuvreux as of…

Press ReleaseNicox : Half-year liquidity contract statement with Kepler Cheuvreux as of December 31, 2023January 8, 2024 – release at 7:30 am CET Sophia Antipolis, FranceUnder the liquidity contract entered into between NICOX and Kepler Cheuvreux, the following resources appeared on the liquidity account on December 31 st, 2023: 311,067 shares€ 8,541.77Number of executions on buy side on semester: 92Number of executions on sell side on semester: 68Traded volume on buy...
Nasdaq GlobeNewswire
08/01/2024

Novartis Scemblix® shows superior major molecular response (MMR) rates vs…

MEDIA & INVESTOR RELEASE Novartis Scemblix ®shows superior major molecular response (MMR) rates vs. standard-of-care TKIs in Phase III trial for newly diagnosed patients with chronic myeloid leukemiaAd hoc announcement pursuant to Art. 53ASC4FIRST trial met both primary endpoints with clinically meaningful and statistically significant results; Scemblix® (asciminib) shows superior MMR rates at week 48 vs. standard-of-care TKIs (imatinib, nilotinib, dasatinib, and...
Nasdaq GlobeNewswire
08/01/2024

ReadyWise, Authorized UN Supplier, Joins Forces with FAO to Provide Critical…

The key benefits of the provided meals are the following: The key benefits of the provided meals are the following: "We are grateful to have incorporated ReadyWise freeze-dried emergency meals into our operation, because of their superior shelf-life without refrigeration in harsh conditions, which is a key requirement for us. In humanitarian operations, having reliable and nutritious food is essential for maintaining the health and resilience of our staff, especially in emergencies"…
PR Newswire
08/01/2024

Vivoryon Therapeutics N.V. to Host Investor Meetings in January 2024

Vivoryon Therapeutics N.V. to Host Investor Meetings in January 2024 Halle (Saale) / Munich, Germany, January 8, 2024– Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY; NL00150002Q7) ( Vivoryon ), a clinical stage company focused on the discovery and development of small molecule medicines to modulate the activity and stability of pathologically altered proteins, today announced that members of its management team including CEO Frank Weber, MD, CBO Michael Schaeffer, PhD, and CS...
Nasdaq GlobeNewswire
08/01/2024

Pharming Group announces updated full year 2023 guidance and Joenja® U.S. launch…

Expect 10% growth in RUCONEST® revenue, significantly exceeding prior guidanceExpect Joenja® revenues of approximately US$18 million with 81 patients on paid therapy at year end Leiden, The Netherlands, January 8, 2024:Pharming Group N.V. (“Pharming” or “the Company”) (EURONEXT Amsterdam: PHARM/Nasdaq: PHAR) announces today updated full year 2023 guidance, including RUCONEST® and Joenja® revenues, and a progress update on the U.S. launch of Joenja® (leniolisib) for APDS...
Nasdaq GlobeNewswire
08/01/2024

Juniper Biologics Clinches Prestigious Molecular Science & Technology…

Caris Molecular Intelligence® is a patented service that uses technologies, such as next-generation sequencing, to examine each tumour at the various biological stages of cancer. This provides individualised data on the molecular characteristics of a patient's cancer, enabling oncologists to make informed treatment decisions. Caris Molecular Intelligence® is a patented service that uses technologies, such as next-generation sequencing, to examine each tumour at the various biological stages of…
PR Newswire
08/01/2024

Shanghai Argo Announces Multi-Program RNAi Licenses and Strategic Collaborations…

- Discovered and developed with Argo's advanced RNA interference (RNAi) technology, these programs will reinforce and expand the Novartis RNAi portfolio on Cardiovascular and Metabolic diseases (CVM). - Discovered and developed with Argo's advanced RNA interference (RNAi) technology, these programs will reinforce and expand the Novartis RNAi portfolio on Cardiovascular and Metabolic diseases (CVM). SHANGHAI,Jan. 7, 2024/PRNewswire/ -- Shanghai Argo Biopharmaceutical Co., Ltd…
PR Newswire
08/01/2024
Altri  Comunicati